AI Article Synopsis
- The study aimed to see if a single AAV vector containing Cas9 and specific guide RNAs could stop the growth of tumors caused by HPV16.
- Researchers used patient-derived anal cancer explants in mice and injected them with AAV vectors that targeted HPV16 genes.
- Results showed that targeting the E6 and E7 genes with Cas9 led to a significant reduction in tumor growth, suggesting that CRISPR/Cas technology could help treat HPV-related tumors in humans.
Article Abstract
Aim: The goal of this study was to determine if a single AAV vector, encoding Cas9 and guide RNAs specific for the HPV16 E6 and E7 genes, could inhibit the growth of an HPV16-induced tumor .
Materials & Methods: We grew HPV16, patient-derived anal cancer explants in immunodeficient mice and then challenged these by injection of AAV-based vectors encoding Cas9 and control or HPV16-specific guide RNAs.
Results & Conclusion: We observed a significant and selective reduction in tumor growth when the HPV16 E6 and E7 genes were targeted using Cas9. These studies provide proof of principle for the hypothesis that CRISPR/Cas has the potential to be used to selectively treat HPV-induced tumors in humans.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6136077 | PMC |
| http://dx.doi.org/10.2217/fvl-2018-0010 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!